Q-omics provides the consensus-scored LOH12CR2 profile across patient tissues and cancer cell-line models. LOH12CR2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, LOH12CR2 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, LOH12CR2 RNA expression shows 18,237 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, KIRC, and UVM as cancer lineages where LOH12CR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LOH12CR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LOH12CR2 survival associations across molecular data types. LOH12CR2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LOH12CR2 RNA expression–survival associations across cancer types. High LOH12CR2 expression shows favorable associations in UCS, KIRP, KIRC, PAAD, ACC and ESCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for LOH12CR2 RNA expression.
This table summarizes LOH12CR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LOH12CR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LOH12CR2 shows lower tumor expression in KIRC, THCA, KICH, BLCA, LUAD and KIRP. The KIRC box plot shows higher LOH12CR2 RNA expression in normal versus tumor tissue (log2 FC = −1.080, t-test p < 0.001).
This table shows molecular features associated with LOH12CR2 in patient tissues and cancer cell lines. In patient samples, LOH12CR2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
